HK Stock Market Move | JBM HEALTHCARE (02161) falls more than 12% with a year-on-year increase in net profit of about 1.9%, with a final dividend of 7.35 Hong Kong cents per share.
Healthcare Biotech (02161) fell over 12%, as of the time of writing, down 12.28% to 2 Hong Kong dollars, with a trading volume of 4.1982 million Hong Kong dollars.
JBM HEALTHCARE (02161) fell more than 12%, dropping by 12.28% to 2 Hong Kong dollars, with a turnover of 4.1982 million Hong Kong dollars as of the time of publication.
On the news front, JBM HEALTHCARE announced its annual performance for the year ending March 31, 2026, with revenue of approximately 835 million Hong Kong dollars, an increase of about 6.7% year-on-year; the company's attributable net profit to equity holders was approximately 201 million Hong Kong dollars, an increase of about 1.9% year-on-year; earnings per share were 24.63 Hong Kong cents, with a final dividend of 7.35 Hong Kong cents per share. The announcement stated that the revenue growth was mainly driven by the strong performance of the branded pharmaceuticals and branded Chinese medicine divisions, partially offset by the underperformance of health and wellness products.
Related Articles

Decomposing the last mile of landing medical AI: YIDU TECH (02158) 280 intelligent beings have entered the clinic.

New stock outlook | Marketing business repair is difficult to hide transformation anxiety: Midodo, with high growth in performance, still needs to break through operational business

TRISTATE HOLD(00458): Wang Guyizhen resigns as a non-executive director.
Decomposing the last mile of landing medical AI: YIDU TECH (02158) 280 intelligent beings have entered the clinic.

New stock outlook | Marketing business repair is difficult to hide transformation anxiety: Midodo, with high growth in performance, still needs to break through operational business

TRISTATE HOLD(00458): Wang Guyizhen resigns as a non-executive director.

RECOMMEND





